Last reviewed 2026-04-23 · How we verify

antiperspirant cream F511

Swiss Cancer Institute · Phase 3 active Small molecule

antiperspirant cream F511 is a Small molecule drug developed by Swiss Cancer Institute. It is currently in Phase 3 development for Hyperhidrosis or excessive sweating (presumed, based on antiperspirant classification).

Antiperspirant cream F511 reduces sweat production by blocking eccrine sweat gland activity, likely through aluminum salt-based or similar astringent mechanisms.

Antiperspirant cream F511 reduces sweat production by blocking eccrine sweat gland activity, likely through aluminum salt-based or similar astringent mechanisms. Used for Hyperhidrosis or excessive sweating (presumed, based on antiperspirant classification).

At a glance

Generic name	antiperspirant cream F511
Sponsor	Swiss Cancer Institute
Modality	Small molecule
Therapeutic area	Dermatology
Phase	Phase 3

Mechanism of action

The drug functions as a topical antiperspirant, working to inhibit or reduce perspiration at the skin surface. The exact molecular mechanism is not publicly detailed, but antiperspirants typically work by forming a plug in sweat ducts or by reducing sweat secretion through aluminum compounds or alternative active ingredients. As a Phase 3 candidate from Swiss Cancer Institute, it may have been developed for specific clinical applications beyond cosmetic use.

Approved indications

Hyperhidrosis or excessive sweating (presumed, based on antiperspirant classification)

Common side effects

Skin irritation or contact dermatitis
Allergic reaction to active ingredients
Local erythema or rash

Key clinical trials

F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast Cancer (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

antiperspirant cream F511 CI brief — competitive landscape report
antiperspirant cream F511 updates RSS · CI watch RSS
Swiss Cancer Institute portfolio CI

Frequently asked questions about antiperspirant cream F511

What is antiperspirant cream F511?

antiperspirant cream F511 is a Small molecule drug developed by Swiss Cancer Institute, indicated for Hyperhidrosis or excessive sweating (presumed, based on antiperspirant classification).

How does antiperspirant cream F511 work?

Antiperspirant cream F511 reduces sweat production by blocking eccrine sweat gland activity, likely through aluminum salt-based or similar astringent mechanisms.

What is antiperspirant cream F511 used for?

antiperspirant cream F511 is indicated for Hyperhidrosis or excessive sweating (presumed, based on antiperspirant classification).

Who makes antiperspirant cream F511?

antiperspirant cream F511 is developed by Swiss Cancer Institute (see full Swiss Cancer Institute pipeline at /company/swiss-cancer-institute).

What development phase is antiperspirant cream F511 in?

antiperspirant cream F511 is in Phase 3.

What are the side effects of antiperspirant cream F511?

Common side effects of antiperspirant cream F511 include Skin irritation or contact dermatitis, Allergic reaction to active ingredients, Local erythema or rash.

Manufacturer: Swiss Cancer Institute — full pipeline
Therapeutic area: All drugs in Dermatology
Indication: Drugs for Hyperhidrosis or excessive sweating (presumed, based on antiperspirant classification)